Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?

Pfizer (NYSE: PFE) is highly likely to survive the current headwinds it faces in the pharmaceutical sector. It has a long history and a strong core business. But it isn't the only drugmaker that's going to muddle through this period in relative stride. If you're looking at Pfizer's 7.1% dividend yield and wondering if you should buy the stock, stop. Here are two alternatives that you may want to consider instead.The pharmaceutical industry has a big-picture problem today because of changes that have taken shape in Washington, D.C. and among consumers. Essentially, there is less trust and support for drug companies right now, particularly when a company's product list includes vaccines. That's one reason why Pfizer is so unloved right now. It's also why Merck (NYSE: MRK) and Bristol-Myers Squibb (NYSE: BMY) are so unloved. In other words, this is an industry issue, not a company-specific one.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool